Safety of inhaled proteins for therapeutic use

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 11, Issue 4, 1998, Pages 197-219

  Wolff, R K ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Inhaled drugs; Lung delivery; Pharmaceuticals; Pulmonary delivery

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; ALPHA INTERFERON; ANTIBIOTIC AGENT; CALCITONIN; DEOXYRIBONUCLEASE; DORNASE ALFA; GAMMA INTERFERON; GROWTH HORMONE; HEPARIN; HUMAN GROWTH HORMONE; INSULIN; LEUPRORELIN; PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADVERSE DRUG REACTION; AEROSOL; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG HALF LIFE; HUMAN; IMMUNE RESPONSE; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG DISEASE; LUNG EMPHYSEMA; LUNG TOXICITY; NONHUMAN; REVIEW; SMOKING; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031646537     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.1998.11.197     Document Type: Review

References (112)

1. Wearley, L.L. 1991. Recent progress in protein and peptide delivery by noninvasive routes. Crit. Rev. Ther. Drug Carrier Sys. 8:331-394.
2. O'Hagan, D.T., and L. Illum. 1990. Absorption of peptides and proteins from the respiratory tract and potential for development of locally administered vaccine. Crit. Rev. Ther. Drug Carrier Sys. 7:35-97.
3. Byron, P.R., and J.S. Patton. 1994. Drug delivery via the respiratory tract. J. Aerosol Med. 7:49-75.
4. Niven, R.W. 1995. Delivery of biotherapeutics by inhalation aerosol. Crit. Rev. Ther. Drug Carrier Syst. 12:151-231.
5. Gansslen, M. 1925. Uber inhalation von insulin. Wien Klin. Wochenschr. 4:71-81.
6. Laube, B.L., A. Georgopoulos, and G.K.I. Adams. 1993. Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. JAMA 269:2106-2109.
7. Brain, J.D., P.A. Valberg, and S. Sneddon. 1985. Mechanisms of aerosol deposition and clearance. In F. Moren, M.T. Newhouse, and M.B. Dolovich, eds. Aerosols in Medicine: Principles, Diagnosis, and Therapy. Elsevier, Amsterdam, 123-148.
8. Thurlbeck, W.M. 1967. The internal surface area of nonemphysematous lungs. Am. Rev. Respir. Dis. 95:765-770.
9. Stone, K.C., R.R. Mercer, P. Gehr, B. Stockstill, and J.D. Crapo. 1992. Allometric relationships of cell numbers and size in the mammalian lung. Am. Rev. Respir. Cell Mol. Biol. 6:235-243.
10. Weibel, E.R. 1963. Morphometry of the Human Lung. Springer Verlag, New York.
11. Staub, N.C., and K.H. Albertine. 1988. The structure of the lungs relative to their principal function. In J.F. Murray, and J.A. Nadel, eds. Textbook of Respiratory Medicine. Saunders, Philadelphia, 12-36.
12. Pinkerton, K.E., P. Gehr, and J.D. Crapo. 1992. Architecture and cellular composition of the air-blood barrier. In R.A. Parent, ed. Comparative Biology of the Human Lung, vol. 1. CRC Press, Boca Raton, 121-128.
13. Effros, R.M., and G.R. Mason. 1983. Measurements of pulmonary epithelial permeability in vivo. Am. Rev. Respir. Dis. 127 (suppl):S59-S66.
14. Hastings, R.H., M. Grady, T. Sakuma, and M.A. Matthay. 1992. Clearance of different-sized proteins from the alveolar space in humans and rabbits. J. Appl. Physiol. 73:1310-1316.
15. Folkesson, H.G., M.A. Matthay, B.R. Westrom, K.J. Kim, B.W. Karlsson, and R.H. Hastings. 1996. Alveolar epithelial clearance of protein. J. Appl. Physiol. 80:1431-1445.
16. Kobayashi, S., S. Kondo, and K. Juni. 1996. Critical factors on pulmonary absorption of peptides and proteins (diffusional barrier and metabolic barrier). Eur. J. Pharm. Sci. 4:367-372.
17. Pillai, R.S., B.L. Hughes, R.K. Wolff, J.A. Heisserman, and M.A. Dorato. 1996. The effect of pulmonary-delivered insulin on blood glucose levels using two nebulizer systems. J. Aerosol Med. 9:227-239.
18. Adjei, A., and J. Garren. 1990. Pulmonary delivery of peptide drugs: Effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers. Pharmacol. Res. 7:565-569.
19. Elliott, R.B., B.W. Edgar, C.C. Pilcher, C. Quested, and J. McMaster. 1987. Parenteral absorption of insulin from the lung in diabetic children. Aust. Paediatr. J. 23:293-297.
20. Kohler, D., K.J. Schluter, L. Kerp, and H. Matthys. 1987. Nicht radioaktives verfahrenzur Messung der Lungenpermeabilitat: Inhalation von Insulin Atemw. Lungenkrkh. Jahrgang. 13:230-232.
21. Deftos, L.J., B.L. Seely, P.C. Clopton, G.J. Cole, C.L. Witham, L.J. Florek, T.A. Christensen and M.R. Hill. 1996. Intrapulmonary delivery of bone-active peptides: Bioactivity of inhaled salmon calcitonin approximates that of injected calcitonin. In Proceedings of Am. Soc. Bone Min. Res. Annual Meeting, Seattle.
22. Borson, D.B. 1991. Roles of neutral endopeptidase in airways. Am. J. Physiol. Lung Cell. Mol. Physiol. 4(suppl):L212-L225.
23. Johnson, A.R., J. Aston, W.W. Schulz, and E.G. Erdos. 1985. Neutral metalloendopeptidase in human lung tissue and cultured cells. Am. Rev. Respir. Dis. 132:564-568.
24. Adjei, A.L., and P.J. Carrigan. 1992. Pulmonary bio-availability of LH-RH analogs: Some biopharmaceutical guidelines. J. Biopharm. Sci. 3:247-254.
25. Jeffrey, P.K., and L.M. Reid. 1977. The respiratory mcuous membrane. In J.D. Brain, D.F. Proctor, and L.M. Reid, eds. Respiratory Defense Mechanisms. Marcel Dekker, New York, 193-245.
26. Wolff, R.K. 1992. Mucociliary function. In R.A. Parent, ed. Treatise on Pulmonary Toxicology: Comparative Biology of the Normal Lung. CRC Press, Boca Raton, 659-680.
27. Luchtel, D.L. 1976. Ultrastructural observations on the mucous layer in pulmonary airways [abstract]. J. Cell Biology. 70:350a.
28. Sayani, A.P., and Y.W. Chien. 1996. Systemic delivery of peptides and proteins across absorptive mucosae. Crit. Rev. Ther. Drug Carrier Sys. 13:85-184.
29. Donovan, M.D., G.L. Flynn, and G.L. Amidon. 1990. Absorption of polyethylene glycols 600 through 2000: The molecular weight dependence of gastrointestinal and nasal absorption. Pharm. Res. 7:863-868.
30. Colthorpe, P., S.J. Farri, I.J. Smith, D. Wyatt, and G. Taylor, 1995. The influence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth hormone in rabbits. Pharm. Res. 12:356-359.
31. Niven, R.W., K.L. Whitcomb, O.B. Kinstler, A.Y. Ip, and L. Shaner. 1995. The pulmonary absorptions of aerosolized and intratracheally instilled rhG-CSF and monoPEGylated rhG-CSF. Pharm. Res. 12:1143-1149.
32. Patton, J.S. 1996. Mechanisms of macromolecule absorption by the lungs. Adv. Drug Deliv. Rev. 19:3-36.
33. Welty-Wolf, K.E., S.G. Simonson, Y.-C.T. Huang, S.P. Kantrow, M.S. Carraway, L.-Y. Chang J.D. Crapo, and C.A. Piantadosi. 1997. Aerosolized manganese SOD decreases hyperoxic pulmonary injury in primates. II. Morphometric analysis. J. Appl. Physiol. 83:559-568.
34. Bensch, K.G., E.A. Dominguez, and A.A. Liebow. 1967. Absorption of intact protein molecules across the pulmonary air-tissue barrier. Science. 157:1204-1206.
35. Berthiaume, Y., K.H. Albertine, M. Grady, G. Fick, and M.A. Matthay. 1989. Protein clearance from the air spaces and lungs of unanesthetized sheep over 144 h. J. Appl. Physiol. 67:1887-1897.
36. Folkesson, H.G., B.R. Westrom, and B.W. Karlsson. 1990. Permeability of the respiratory tract to different-sized macromolecules after intratracheal instillation in young and adult rats. Acta Physiol. Scand. 139:347-354.
37. Matthay, M., Y. Berthiaume, and N.C. Staub. 1985. Long-term clearance of liquid and protein from the lungs of unanesthetized sheep. J. Appl. Physiol. 59:928-934.
38. Kim, K.-J., and E.D. Crandall. 1996. Role of endocytotic pathways in alveolar epithelial transport of macromolecules. In R.N. Dalby, P.R. Byron, and S.J. Farr, eds. Respiratory Drug Delivery V. Interpharm Press, Buffalo Grove, IL, 153-159.
39. Schneeberger-Keeley, E.E., and M.J. Karnovsky. 1968. The ultrastructural basis of alveolarcapillary membrane permeability to peroxidase used as a tracer. J. Cell. Biol. 37:781-793.
40. Bignon, J., M.C. Jaurand, M.C. Pinchon, C. Sapin, and J.M. Warner. 1976. Immunoelectron microscopic and immunochemical demonstrations of serum proteins in the alveolar lining material of the rat lung. Am. Rev. Respir. Dis. 113:104-120.
41. Williams, M.C. 1984. Endocytosis in type II cells: Effect of charge and size of tracer. Proc. Natl. Acad. Sci. USA. 81:6054-6058.
42. Sorokin, S.P., and J.D. Brain. 1974. Pathways of clearance in mouse lungs exposed to iron oxide aerosols. Anat. Rec. 181:581-626.
43. Adamson, I.Y.R., and D.H. Bowden. 1981. Dose response of the pulmonary macrophage system to various particulates and its relation to transepithelial passage of free particles. Exp. Lung Res. 2:165-175.
44. Kim, K.J., V. Rattan, P. Oh, J.E. Schnitzer, V.K. Kalra, and E.D. Crandall. 1995. Specific-albumin binding protein in alveolar epithelial cell monolayers [abstract]. Am. J. Respir. Crit. Care. 151:A190.
45. Murphy, L.J., E. Vrhousek, and L. Lazarus. 1983. Identification and characterization of specific growth hormone receptors in cultured human fibroblasts. J. Clin. Endolog. Metab. 57:1117-1124.
46. Hastings, R.H., H. Duong, D.W. Burton, and L.J. Deftos. 1994. Alveolar epithelial cells express and secrete parathyroid hormone-related protein. Am. J. Respir. Cell Mol. Biol. 11:701-706.
47. Zinman, B. 1989. The physiologic replacement of insulin. N. Engl. J. Med. 321:363-369.
48. American Diabetes Association. 1991. Clinical practice recommendations: American Diabetes Association 1990-1991. Diabetes Care. 14:30-33.
49. Morrow, P.E. 1992. Dust overloading of the lungs: Update and appraisal. Toxicol. Appl. Pharmacol. 113:1-12.
50. Mauderly, J.L., Y.-S. Cheng, and M.B. Snipes. 1990. Particle overload in toxicological studies: Friend or foe? J. Aerosol Med. 3(suppl):S169-S187.
51. Muhle, H., O. Creutzenberg, B. Bellmann, U. Heinrich, and R. Mermelstein. 1990. Dust overloading of the lungs: Investigations of various materials, species differences, and irreversibility of effects. J. Aerosol Med. 3:S111-S128.
52. Warheit, D.B., J.F. Hansen, I.S. Yuen, S.I. Snadjdr, and M.A. Hartsky. 1996. Prolonged cell proliferation and pulmonary inflammation are produced in rats inhaling high concentrations of low-toxicity insoluble particulates: Comparisons with cytotoxic dusts. In J.L. Mauderly, and R.J. McCunney, eds. Particle Overload in the Rat Lung and Lung Cancer: Implications for Risk Assessment. Taylor & Francis, Washington, DC, 155-168.
53. Driscoll, K.E. 1996. Role of inflammation in the development of rat lung tumors in response to chronic particle exposure. In J. L. Mauderly, and R.J. McCunney, eds. Particle Overload in the Rat Lung and Lung Cancer: Implications for Human Risk Assessment. Taylor & Francis, Washington, DC, 139-154.
54. Ogden J., C. Rogerson, and I. Smith. 1996. Issues in pulmonary delivery. Scrip. 2063:56-60.
55. Patton, J.S., and R.M. Platz. 1994. Aerosol insulin-a brief review. In P.R. Byron, ed. Respiratory Drug Delivery IV. Interpharm Press, Buffalo Grove, IL, 65-74.
56. Kinnula, V., K. Cantell, and K. Mattson. 1990. Effect of inhaled natural interferon-alpha on diffuse bronchioalveolar carcinoma. Eur. J. Cancer 26:740-741.
57. Martin, R.J., M. Boguniewicz, J.E. Henson, A.C. Celniker, M. Williams, R.C. Giorno, and D.Y. Leung. 1993. The effects of inhaled interferon gamma in normal human airways. Am. Rev. Respir. Dis. 148:1677-1682.
58. Adjei, A.L. 1995. Regulatory issues concerning systemic delivery via the respiratory tract: Leuprolide as a demonstration model [abstract]. J. Aerosol Med. 8:131.
59. 1-antitrypsin treatment for cystic fibrosis. Lancet. 337:392-394.
60. Kohler, D. 1994. Aerosolized heparin. J. Aerosol Med. 7:307-314.
61. Hall, C.B. 1989. Aerosolized treatment of acute pulmonary infections. J. Aerosol Med. 2:221-231.
62. McElvaney, N.G. 1996. Gene therapy in cystic fibrosis using viral vectors. In R.N. Dalby, P.R. Byron, and S.J. Farr, eds. Respiratory Drug Delivery V. Interpharm Press, Buffalo Grove, IL, 43-48.
63. Alton, E.W.F.W. 1996. Liposome-mediated gene delivery to the lungs. In R.N. Dalby, P.R. Byron, and S.J. Farr, eds. Respiratory Drug Delivery V. Interpharm Press, Buffalo Grove, IL, 49-54.
64. Pouton, C.W., A.N. Uduehi, and P. Lucas. 1996. Pharmaceutical and biopharmaceutical issues in gene delivery to the lung. In R.N. Dalby, P.R. Byron, and S.J. Farr, eds. Respiratory Drug Delivery V. Interpharm Press, Buffalo Grove, IL, 33-42.
65. United States Food and Drug Administration. 1993. Summary Basis of Approval for Dornase Alfa, recombinant Pulmozyme Inhalation Solution. FDA, Washington, DC.
66. Le Conte, P., G. Potel, P. Peltier, D. Horeau, J. Caillon, M. Juvin, M. Kergueris, D. Bugonon, and D. Baron. 1993. Lung distribution and pharmacokinetics of aerosolized tobramycin. Am. Rev. Respir. Dis. 47:1279-1282.
67. Ilowite, J.S., J.D. Gorvoy, and G.C. Smaldone. 1987. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am. Rev. Respir. Dis. 136:1445-1449.
68. Mahadoo, J., L.M. Hiebert, L.B. Jaques, and C.J. Wright. 1981. Endothelial sequestration of heparin administered by the intrapulmonary route. Artery. 7:438-447.
69. Bick, R.L., and E.S. Ross. 1985. Clinical use of intrapulmonary heparin. Semin. Thromb. Hemost. 11:213-217.
70. Crystal, R.G., N.G. McElvaney, M.A. Rosenfeld, C.S. Chu, A. Mastrangeli, J.G. Hay, S.L. Brody, H.A. Jaffe, N.T. Eissa, and C. Danel. 1994. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet. 8:42-50.
71. Green, J.D. 1994. Pharmaco-toxicological expert report: Pulmozyme™, rhDNase, Genentech, Inc. Hum. Exp. Toxicol. 13(suppl):S1-S42.
72. 1-antitrypsin in rats following subacute inhalation exposure. In Proceedings of the Fourth International Aerosol Conference, Los Angeles, CA, p. 683 (abstract).
73. Patton, J.S., and R.M. Platz. 1992. Pulmonary delivery of peptides and proteins for systemic action. Adv. Drug Deliv. Rev. 8:179-196.
74. Hurst, T.S., and J.A. Dosman. 1990. Characterization of health effects of grain dust exposure. Am. J. Ind. Med. 17:27-32.
75. Stepner, N., I. Broder, and R. Baumal. 1986. Animal model of grain worker's lung. Environ. Health Perspect. 66:31-35.
76. Bout, A., J.-L. Imler, H. Schultz, M. Perricaudet, C. Zurcher, P. Herbrink, D. Valerio, and A. Pavirani. 1994. In vivo adenovirus-mediated transfer of human CFTR cDNA to rhesus monkey airway epithelium, toxicity, and safety. Gene Therapy 1:385-394.
77. Zabner, J., D.M. Peterson, A.P. Puga, S.M. Graham, L.A. Couture, L.D. Keyes, M.J. Lukason, J.A. St. George, R.J. Gregory, A.E. Smith, and M.J. Welsh. 1994. Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nat. Genet. 6:75-83.
78. Curiel, D.T., J.M. Pilewski, and S.M. Albelda. 1996. Gene therapy approaches for inherited and acquired lung diseases. Am. J. Respir. Cell Med. Biol. 14:1-18.
79. Newhouse, M.T., and R.E. Ruffin. 1978. Deposition and fate of aerosolized drugs. Chest. 73:936-943.
80. Newman, S.P., and D. Pavia. 1985. Aerosol deposition in man. In F. Moren, M.T. Newhouse, and M.B. Dolovich, eds. Aerosols in Medicine. Elsevier, Amsterdam, 193-218.
81. Smaldone, G.C. 1994. Deposition patterns of nebulized drugs: Is the pattern important? J. Aerosol Med. 7(suppl):S25-S32.
82. Youngchaiyud, P., L.J. Kettle, and D.W. Cugell. 1968. The effect of heparin aerosols on air-way conductance in patients with chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 99:449-452.
83. Kohler, D., K.J. Schluter, L. Kerp, and H. Matthys. 1987. Nicht radioaktives Verfahren zur Messung der Lungenpermeabilitat: Inhalation von Insulin. Atemw. Lungenkrkh. 13:230-232.
84. Minty, B.D., C. Jordan, and J.G. Jones. 1981. Rapid improvement in abnormal lung epithelial permeability after stopping cigarettes. BMJ 282:1183-1186.
85. Mason, G.R., J.M. Uszler, R.M. Effros, and E. Reid. 1983. Rapid reversible alterations of pulmonary epithelial permeability. Chest. 83:6-11.
86. Wolff, R.K., M. Dolovich, C.M. Rossman, and M.T. Newhouse. 1975. Sulphur dioxide and tracheobronchial clearance in man. Arch. Environ. Health. 30:521-527.
87. Platz, R.M. 1996. Aerosol delivery of proteins and peptides. In Proceedings of Controlled Release Society Annual Meeting,
88. Solomon, W.R. 1984. Aerobiology of pollinosis. J. Allergy Clin. Immunol. 74:449-461.
89. Roitt, I.M., J. Brostoff, and D.K. Male. 1989. Essential Immunology. Gower Medical Publishing, London.
90. Busse, W., and S. Holgate. 1995. Asthma and Rhinitis. Blackwell Scientific Publications, Boston.
91. Lopez, M., and I.E. Salvaggio. 1988. Hypersensitivity pneumonitis. In J.F. Murray, and J.A. Nadel, eds. Textbook of Respiratory Medicine. W.B. Saunders, Philadelphia, 1606-1617.
92. Platts-Mills, T.A.E. 1994. How environment affects patients with allergic disease: Indoor allergens and asthma. Ann Allergy. 72:381-384.
93. Wheatley, L.M., and T.A.E. Platts-Mills. 1996. Perennial allergens and the asthma epidemic. Science and Medicine. May/June:6-13.
94. United States Environmental Protection Agency. 1996. USEPA, Washington, DC, 7-81-7-106. Air Quality Criteria for Particulate Matter, EPA/600/P-95/001 aF.
95. Newhouse, M.T., and P.J. Barnes. 1991. Conquering Asthma. Decker, Toronto.
96. Home, P.D., N.P. Mann, A.S. Hutchison, R. Park, S. Walford, M. Murphy, and W.G. Reeves. 1984. A fifteen month double-blind cross-over study of the efficacy and antigenicity of human and pork insulins. Diabet. Med. 1:93-98.
97. Wilson, R.M., C.A. Douglas, R.B. Tattersall, and W.G. Reeves. 1985. Immunogenicity of highly purified bovine insulin: A comparison with conventional bovine and highly purified human insulins. Diabetolgia. 28:667-670.
98. Palmer, J.P., C.M. Asplin, P. Clemons, K. Lyon, O. Tapati, R. Raghu, and C. Paquette. 1983. Insulin antibodies in insulin dependent diabetics before insulin treatment. Science. 222: 1337-1339.
99. Home, P.D., and K.G.G.M. Alberti. 1982. The new insulins. Their characteristics and clinical indicators. Drugs. 24:401-413.
100. 2-Macroglobulin, monomeric and polymeric immunoglobulin A, and immunoglobulin M in bronchoalveolar lavage. Am. Rev. Respir. Dis. 132:829-835.
101. Bell, D.Y., J.A. Haseman, A. Spock, G. McLennan, and G.E.R. Hook. 1981. Plasma proteins of the bronchioalveolar surface of the lungs of smokers and nonsmokers. Am. Rev. Respir. Dis. 124:72-79.
102. Reynolds, H.Y., and H.H. Newball. 1974. Analysis of proteins and respiratory cells obtained from human lungs by bronchial lavage. J. Lab. Clin. Med. 84:559-573.
103. Warr, G.A., R.R. Martin, P.M. Sharp, and R.D. Rossen. 1977. Normal human bronchial immunoglobulins and proteins. Am. Rev. Respir. Dis. 116:25-30.
104. Boucher, R.C. 1994. Human airway ion transport-part one. Am. J. Respir. Crit. Care Med. 150:171-185.
105. Rennard, S.I., G. Basset, D. Lecossier, K.M. O'Donnell, P. Pinkston, P.G. Martin, and R.G. Crystal. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J. Appl. Physiol. 60:532-538.
106. +, and albumin concentrations in the alveolar milieu of normal humans and pulmonary sarcoidosis patients. Am. Rev. Respir. Dis. 143:1096-1101.
107. Holt, P.G., D. Britten, and J.D. Sedgwick. 1987. Suppression of IgE responses by antigen inhalation: Studies on the role of genetic and environmental factors. Immunology 60:97-102.
108. Holt, P.G. 1994. Immunonoprophylaxis of atropy: Light at the end of the tunnel? Immunol Today. 15:484-489.
109. American Conference of Governmental Industrial Hygienists. 1995. Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices, vol 2. ACGIH, Cincinnati, 33.
110. United States Environmental Protection Agency. 1992. Respiratory health effect of passive smoking: Lung cancer and other disorders, EPA/600/6-90/006F. USEPA, Washington, DC.
111. Wolff, R.K., and M.A. Dorato. 1993. Toxicologic testing of inhaled pharmaceutical aerosols. Crit. Rev. Toxicol. 23:343-369.
112. Galloway, J.A., C.T. Spradlin, R.L. Nelson, S.M. Wentworth, J.A. Davidson, and J.L. Swarner. 1981. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care. 3:366-376.